Zylstra Medical Limited 08657907 false 2024-09-01 2025-08-31 2025-08-31 The principal activity of the company is general medical practice activities. Digita Accounts Production Advanced 6.30.9574.0 true 08657907 2024-09-01 2025-08-31 08657907 2025-08-31 08657907 core:RetainedEarningsAccumulatedLosses 2025-08-31 08657907 core:ShareCapital 2025-08-31 08657907 core:CurrentFinancialInstruments core:WithinOneYear 2025-08-31 08657907 bus:SmallEntities 2024-09-01 2025-08-31 08657907 bus:AuditExemptWithAccountantsReport 2024-09-01 2025-08-31 08657907 bus:FullAccounts 2024-09-01 2025-08-31 08657907 bus:SmallCompaniesRegimeForAccounts 2024-09-01 2025-08-31 08657907 bus:RegisteredOffice 2024-09-01 2025-08-31 08657907 bus:Director1 2024-09-01 2025-08-31 08657907 bus:PrivateLimitedCompanyLtd 2024-09-01 2025-08-31 08657907 core:MotorVehicles 2024-09-01 2025-08-31 08657907 countries:England 2024-09-01 2025-08-31 08657907 2024-08-31 08657907 2023-09-01 2024-08-31 08657907 2024-08-31 08657907 core:RetainedEarningsAccumulatedLosses 2024-08-31 08657907 core:ShareCapital 2024-08-31 08657907 core:CurrentFinancialInstruments core:WithinOneYear 2024-08-31 iso4217:GBP xbrli:pure

Registration number: 08657907

Zylstra Medical Limited

Annual Report and Unaudited Filleted Abridged Financial Statements

for the Year Ended 31 August 2025

 

Zylstra Medical Limited

Contents

Abridged Balance Sheet

1

Notes to the Unaudited Abridged Financial Statements

2 to 3

 

Zylstra Medical Limited

(Registration number: 08657907)
Abridged Balance Sheet as at 31 August 2025

2025
£

2024
£

Current assets

Cash at bank and in hand

23,746

25,400

Creditors: Amounts falling due within one year

(6,067)

(6,283)

Net assets

17,679

19,117

Capital and reserves

Called up share capital

100

100

Profit and loss account

17,579

19,017

Total equity

17,679

19,117

For the financial year ending 31 August 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime and the option not to file the Profit and Loss Account has been taken.

All of the company’s members have consented to the preparation of an Abridged Profit and Loss Account and an Abridged Balance Sheet in accordance with Section 444(2A) of the Companies Act 2006.

Approved and authorised by the Board on 2 December 2025 and signed on its behalf by:
 

Dr H J Zylstra

Director

 

Zylstra Medical Limited

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 August 2025

1

General information

The company is a private company limited by share capital, incorporated in England.

The address of its registered office is:
Calyx House
South Road
Taunton
Somerset
TA1 3DU

These financial statements were authorised for issue by the Board on 2 December 2025.

2

Accounting policies

Statement of compliance

These abridged financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These abridged financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Tax

The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

 

Zylstra Medical Limited

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 August 2025

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Motor vehicles

20% on a straight line basis

3

Staff numbers

The average number of persons employed by the company (including directors) during the year, was 5 (2024 - 5).

4

Tangible assets

Total
£

Cost or valuation

At 1 September 2024

49,435

At 31 August 2025

49,435

Depreciation

At 1 September 2024

49,435

At 31 August 2025

49,435

Carrying amount

At 31 August 2025

-